Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR12202441

—

2430d5c7-bacf-557e-9989-d707988db7dc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.640
  • INFLAMMATORY_RESPONSE+0.560
  • INTERFERON_GAMMA_RESPONSE+0.560
  • ANGIOGENESIS+0.550
  • TNFA_SIGNALING_VIA_NFKB+0.540
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
  • ALLOGRAFT_REJECTION+0.480
  • HEDGEHOG_SIGNALING+0.480
  • IL6_JAK_STAT3_SIGNALING+0.470
  • COAGULATION+0.440

Top 10 suppressed

  • MYC_TARGETS_V1-0.630
  • MYC_TARGETS_V2-0.590
  • E2F_TARGETS-0.570
  • DNA_REPAIR-0.480
  • OXIDATIVE_PHOSPHORYLATION-0.470
  • G2M_CHECKPOINT-0.450
  • PROTEIN_SECRETION-0.340
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
  • GLYCOLYSIS-0.310
  • MTORC1_SIGNALING-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-60-2715-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.953
2SRR2771286
melanoma-umap@29
——0.943
3c277dab0-361f-4aa6-96b1-522a6e556ae1
colon-landscapes@1
——0.943
4DRR168569
bladder-landscape@3
——0.943
5C3L-02515
lung-landscapes@6
—cohortA10.943
6TCGA-55-6985-01A-11R-1949-07
lung-landscapes@6
—cohortA10.939
72cec663c-00c8-48b5-967b-f2a53c0fb409
colon-landscapes@1
——0.936
8TCGA-A2-A0CO-01A-13R-A22K-07
breast-umap@18
—A0.936
9MDT-AP-1108
medullo-epn-umap@date-based
MedMedulloblastoma0.932
10sclcA055A_S52.txt
lung-landscapes@6
—cohortMD20.932

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.640Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.560Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.560Idelalisib— uncovered
ANGIOGENESIS0.550Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.540Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.490Inavolisib— uncovered
ALLOGRAFT_REJECTION0.480Idelalisib— uncovered
HEDGEHOG_SIGNALING0.480Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.470Inavolisib— uncovered
COAGULATION0.440Binimetinib— uncovered
KRAS_SIGNALING_UP0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
COMPLEMENT0.380Inavolisib— uncovered
KRAS_SIGNALING_DN0.310Remibrutinib— uncovered
MYOGENESIS0.310Inavolisib— uncovered
APICAL_JUNCTION0.290Inavolisib— uncovered
APICAL_SURFACE0.280Temsirolimus— uncovered
APOPTOSIS0.250Idelalisib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.230Inavolisib— uncovered